Cash price roughly $250 to $300 per month
In the drugs best showing so far, the ATTAIN-1 trial, people taking orforglipron lost on average 12.4% of their baseline weight, a notch below the roughly 14% weight loss seen in similar trials of Novo Nordisks injectable Wegovy and also below the typical results seen with Eli Lillys tirzepatide, a dual GLP-1/GIP medication
The bioanalytical method based on liquid chromatography separation, mass spectrometry detection, and sample preparation exhibits good selectivity, high sensitivity, and wide linear range, making them widely used for the quantitative analysis of GLP-1 analogues in bioanalysis
Most favored for active adults focused on body composition, athletes in the off-season, and patients who have tried Sermorelin and want a stronger response